129 related articles for article (PubMed ID: 11678309)
1. VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells.
Moody TW; Leyton J; Chan D; Brenneman DC; Fridkin M; Gelber E; Levy A; Gozes I
Breast Cancer Res Treat; 2001 Jul; 68(1):55-64. PubMed ID: 11678309
[TBL] [Abstract][Full Text] [Related]
2. (N-stearyl, norleucine17) VIP hybrid inhibits the growth of pancreatic cancer cell lines.
Zia H; Leyton J; Casibang M; Hau V; Brenneman D; Fridkin M; Gozes I; Moody TW
Life Sci; 2000; 66(5):379-87. PubMed ID: 10670826
[TBL] [Abstract][Full Text] [Related]
3. A vasoactive intestinal peptide antagonist inhibits the growth of glioblastoma cells.
Sharma A; Walters J; Gozes Y; Fridkin M; Brenneman D; Gozes I; Moody TW
J Mol Neurosci; 2001 Dec; 17(3):331-9. PubMed ID: 11859929
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist.
Zia H; Hida T; Jakowlew S; Birrer M; Gozes Y; Reubi JC; Fridkin M; Gozes I; Moody TW
Cancer Res; 1996 Aug; 56(15):3486-9. PubMed ID: 8758916
[TBL] [Abstract][Full Text] [Related]
5. A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth.
Moody TW; Zia F; Draoui M; Brenneman DE; Fridkin M; Davidson A; Gozes I
Proc Natl Acad Sci U S A; 1993 May; 90(10):4345-9. PubMed ID: 8389448
[TBL] [Abstract][Full Text] [Related]
6. (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.
Moody TW; Jensen RT; Fridkin M; Gozes I
J Mol Neurosci; 2002; 18(1-2):29-35. PubMed ID: 11931347
[TBL] [Abstract][Full Text] [Related]
7. (Stearyl, Norleucine17)VIP hybrid antagonizes VIP receptors on non-small cell lung cancer cells.
Moody TW; Leyton J; Coelho T; Jakowlew S; Takahashi K; Jameison F; Koh M; Fridkin M; Gozes I; Knight M
Life Sci; 1997; 61(17):1657-66. PubMed ID: 9363981
[TBL] [Abstract][Full Text] [Related]
8. A lipophilic vasoactive intestinal peptide analog enhances the antiproliferative effect of chemotherapeutic agents on cancer cell lines.
Gelber E; Granoth R; Fridkin M; Dreznik Z; Brenneman DE; Moody TW; Gozes I
Cancer; 2001 Oct; 92(8):2172-80. PubMed ID: 11596035
[TBL] [Abstract][Full Text] [Related]
9. (Arg15, Arg21) VIP: evaluation of biological activity and localization to breast cancer tumors.
Moody TW; Leyton J; Unsworth E; John C; Lang L; Eckelman WC
Peptides; 1998; 19(3):585-92. PubMed ID: 9533649
[TBL] [Abstract][Full Text] [Related]
10. VIPhyb, an antagonist of vasoactive intestinal peptide receptor, enhances cellular antiviral immunity in murine cytomegalovirus infected mice.
Li JM; Darlak KA; Southerland L; Hossain MS; Jaye DL; Josephson CD; Rosenthal H; Waller EK
PLoS One; 2013; 8(5):e63381. PubMed ID: 23723978
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo treatment of colon cancer by VIP antagonists.
Levy A; Gal R; Granoth R; Dreznik Z; Fridkin M; Gozes I
Regul Pept; 2002 Nov; 109(1-3):127-33. PubMed ID: 12409224
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity.
Plonowski A; Varga JL; Schally AV; Krupa M; Groot K; Halmos G
Int J Cancer; 2002 Apr; 98(4):624-9. PubMed ID: 11920625
[TBL] [Abstract][Full Text] [Related]
13. Receptors for VIP and PACAP in guinea pig cerebral cortex: effects on cyclic AMP synthesis and characterization by 125I-VIP binding.
Zawilska JB; Dejda A; Niewiadomski P; Gozes I; Nowak JZ
J Mol Neurosci; 2005; 25(3):215-24. PubMed ID: 15800375
[TBL] [Abstract][Full Text] [Related]
14. VIP-ellipticine derivatives inhibit the growth of breast cancer cells.
Moody TW; Czerwinski G; Tarasova NI; Michejda CJ
Life Sci; 2002 Jul; 71(9):1005-14. PubMed ID: 12088760
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of vasoactive intestinal polypeptide (VIP) induces resistance to dextran sodium sulfate (DSS)-induced colitis in mice.
Vu JP; Million M; Larauche M; Luong L; Norris J; Waschek JA; Pothoulakis C; Pisegna JR; Germano PM
J Mol Neurosci; 2014 Jan; 52(1):37-47. PubMed ID: 24395090
[TBL] [Abstract][Full Text] [Related]
16. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells.
Jiang S; Kopras E; McMichael M; Bell RH; Ulrich CD
Cancer Res; 1997 Apr; 57(8):1475-80. PubMed ID: 9108448
[TBL] [Abstract][Full Text] [Related]
17. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors.
Virgolini I; Yang Q; Li S; Angelberger P; Neuhold N; Niederle B; Scheithauer W; Valent P
Cancer Res; 1994 Feb; 54(3):690-700. PubMed ID: 7905785
[TBL] [Abstract][Full Text] [Related]
18. An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system.
Gozes I; McCune SK; Jacobson L; Warren D; Moody TW; Fridkin M; Brenneman DE
J Pharmacol Exp Ther; 1991 Jun; 257(3):959-66. PubMed ID: 1646331
[TBL] [Abstract][Full Text] [Related]
19. Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers.
Rekasi Z; Varga JL; Schally AV; Halmos G; Armatis P; Groot K; Czompoly T
Endocrinology; 2000 Jun; 141(6):2120-8. PubMed ID: 10830299
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology, molecular identification and functional characteristics of vasoactive intestinal peptide receptors in human breast cancer cells.
Gespach C; Bawab W; de Cremoux P; Calvo F
Cancer Res; 1988 Sep; 48(18):5079-83. PubMed ID: 2842044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
